tyrosine has been researched along with n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chikazu, D; Hakeda, Y; Itabashi, A; Kawaguchi, H; Kumegawa, M; Nakamura, K; Nemoto, K; Ogata, N; Takato, T | 1 |
| Kanda, N; Watanabe, S | 1 |
| Carluccio, MA; De Caterina, R; Distante, A; Massaro, M; Scoditti, E; Storelli, C | 1 |
3 other study(ies) available for tyrosine and n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
| Article | Year |
|---|---|
Fibroblast growth factor (FGF)-2 directly stimulates mature osteoclast function through activation of FGF receptor 1 and p42/p44 MAP kinase.
Topics: Animals; Blotting, Northern; Bone and Bones; Cathepsin K; Cathepsins; Cell Survival; Cells, Cultured; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fibroblast Growth Factor 2; Flavonoids; Immunoblotting; Kinetics; Male; Matrix Metalloproteinase 2; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Nitrobenzenes; Osteoblasts; Osteoclasts; Phosphorylation; Precipitin Tests; Protein-Tyrosine Kinases; Rabbits; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptor, Fibroblast Growth Factor, Type 4; Receptors, Fibroblast Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sulfonamides; Time Factors; Tyrosine; Up-Regulation | 2000 |
Cyclooxygenase-2 inhibitor enhances whereas prostaglandin E2 inhibits the production of interferon-induced protein of 10 kDa in epidermoid carcinoma A431.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL10; Chemokines, CXC; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Gene Expression; Humans; Interferon-Stimulated Gene Factor 3; Isoenzymes; Janus Kinase 1; Janus Kinase 2; Membrane Proteins; Nitrobenzenes; Phosphorylation; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptors, Prostaglandin E; Response Elements; RNA, Messenger; Signal Transduction; Skin Neoplasms; Sulfonamides; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured; Tyrosine | 2002 |
PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium.
Topics: Angiogenesis Inhibitors; Anilides; Benzhydryl Compounds; Benzophenones; Binding Sites; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Down-Regulation; Endothelial Cells; Epoxy Compounds; Gene Expression Regulation, Enzymologic; Humans; Neovascularization, Physiologic; Nitrobenzenes; PPAR gamma; Promoter Regions, Genetic; Protein Kinase C-alpha; Protein Transport; RNA Interference; RNA, Messenger; Rosiglitazone; Sulfonamides; Tetradecanoylphorbol Acetate; Thiazolidinediones; Transfection; Tyrosine; Vascular Endothelial Growth Factor A | 2010 |